Red Eye News and Research

RSS

New, safer CRISPR approach may help correct genetic defects in the future

Curing debilitating genetic diseases is one of the great challenges of modern medicine. During the past decade, development of CRISPR technologies and advancements in genetics research brought new hope for patients and their families, although the safety of these new methods is still of significant concern.

1 Jul 2022

Research provides new insights into debilitating cluster headaches

Debilitating cluster headaches commonly begin in childhood, but patients are not typically diagnosed until they are adults, according to research from The University of Texas Health Science Center at Houston.

8 Dec 2021

Weekly exposure to deep red light in the morning can improve declining vision

Just three minutes of exposure to deep red light once a week, when delivered in the morning, can significantly improve declining eyesight, finds a pioneering new study by UCL researchers.

24 Nov 2021

Study provides genomic insights into life history tradeoffs in butterflies

Have you ever wandered through your garden or a meadow on a summer day and wondered why and how butterflies exhibit such beautiful and diverse colors? Scientists have, especially when thinking about butterflies in the genus Colias. In most Colias butterflies, all males and most females are an orange or yellow color, but some females are white.

18 Dec 2019

Common sense concerns over Nerf gun eye injuries from doctors

Thousands of children worldwide play with Nerf guns. Doctors are now concerned about the potential for these guns to harm the eyes and lead to serious eye injuries.

19 Sep 2017

Study opens the lid on overprescribing of antibiotics for acute conjunctivitis

A new study suggests that most people with acute conjunctivitis, or pinkeye, are getting the wrong treatment.

29 Jun 2017

Most people with acute conjunctivitis get wrong treatment, study suggests

A new study suggests that most people with acute conjunctivitis, or pink eye, are getting the wrong treatment. About 60 percent of patients are prescribed antibiotic eyedrops, even though antibiotics are rarely necessary to treat this common eye infection.

19 Jun 2017

First case of Zika virus found in Ohio

"This is not unexpected," says Frank Esper, MD, infectious disease specialist at University Hospitals Rainbow Babies & Children's Hospital in Cleveland, after learning of the first case of Zika virus in Ohio, found in a Cleveland woman who traveled to Haiti. "We know people are going to come back and they're going to have the Zika virus."

11 Feb 2016

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015

Significant divide can exist between patients and physicians about same medical terms

Few things are more stressful than dealing with a sick child. From discussing treatment with a pediatrician to complying with day care policies, a parent must consider many factors when making a decision about their child's health. Now, a recent study from the University of Missouri and the University of Michigan is shedding light on the significant divide that can exist between patients and physicians about the same terminology--especially when it comes to discussing "pink eye," a particular flashpoint in childcare.

25 Aug 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

OAO report calls for better care for people living with eye disease, vision problems in Ontario

By 2031, the number of Ontarians living with eye disease and vision problems, already in the millions, is expected to double. This leads to significant costs for Ontario's healthcare system, with vision loss already costing the province $7.3 billion annually.

28 Apr 2015

CHLA infectious diseases specialist discusses how parents can prevent measles outbreak

Since December, there have been more than 130 confirmed cases of measles in the state of California, most of them connected to an outbreak that originated in a Southern California amusement park. Many of the infected persons were not vaccinated against the extremely contagious virus, which manifests itself through rash, fever and coughing.

6 Apr 2015

Laundry detergent pods are dangerous for young children

Laundry detergent pods began appearing on U.S. store shelves in early 2010, and people have used them in growing numbers ever since. The small packets can be tossed into a washing machine without ever having to measure out a liquid or powder. The convenience, though, has come with risks for young children.

11 Nov 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing non-antibiotic, topical antimicrobial products, today announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation.

16 May 2014

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Amakem Therapeutics, a clinical stage ophthalmology company, today announced that first patients have commenced treatment in a Phase 2 dose-ranging study of its lead drug candidate, AMA0076 for the treatment of glaucoma.

13 May 2014

Viral conjunctivitis: potential new treatment

Viral conjunctivitis is a highly contagious infection, often causing major ophthalmic epidemics. There is no approved acute treatment currently approved by the FDA for viral conjunctivitis. A safe broad-spectrum antiviral agent is needed to treat this unmet medical need.

5 Feb 2013

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.

27 Sep 2012

Positive results from Bausch + Lomb, NicOx BOL‑303259‑X phase 2b study on OAG

Bausch + Lomb, the global eye health company, and NicOx S.A. today announced positive top-line results from the phase 2b study conducted with BOL‑303259‑X, a novel nitric oxide-donating prostaglandin F2‑alpha analog, in patients with open-angle glaucoma or ocular hypertension.

13 Mar 2012